INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6301, 32982, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6302, 32983, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6303, 33198, 'Methotrexate', 'Bone Marrow Failure Disorders', 'Methotrexate can induce myelosuppression causing leukopenia, thrombocytopenia, neutropenia, pancytopenia and anemia.  Therapy with methotrexate is contraindicated as treatment of psoriasis in patients with bone marrow suppression or preexisting blood dyscrasias.  Methotrexate should be discontinued immediately in patients with psoriasis or rheumatoid arthritis if there is a significant fall in blood cell counts.  If need outweighs risk, therapy with methotrexate should be administered cautiously in patients with malignancy and hematopoietic impairment.  Additionally, methotrexate should be used with extreme caution in patients with active infection, and it is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression or infection such as fever, sore throat, or bleeding.  Clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6304, 5019, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6305, 8089, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6306, 11930, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6307, 14338, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6308, 14594, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6309, 18291, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6310, 22641, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6311, 22644, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6312, 22645, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6313, 22647, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6314, 22648, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6315, 22649, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6316, 22650, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6317, 22651, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6318, 22652, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6319, 22653, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6320, 22654, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6321, 22655, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6322, 22657, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6323, 22786, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6324, 23055, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6325, 23056, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6326, 28776, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6327, 28778, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6328, 28779, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6329, 32982, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6330, 32983, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6331, 33198, 'Methotrexate', 'Kidney Diseases', 'Methotrexate is primarily eliminated by the kidney via glomerular filtration and active secretion.  Clearance rates for methotrexate vary and at higher doses are generally decreased due to saturation of renal tubular reabsorption.  Renal impairment or third space effusion (ascites, pleural effusions), decrease elimination and increase methotrexate serum concentrations.  Therapy with methotrexate should be administered cautiously and at reduced dosages in patients with compromised renal function.  Administration of leucovorin reduces toxicity from high dose methotrexate regimens or delayed elimination.  Clinical monitoring of renal function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6332, 5019, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6333, 8089, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6334, 11930, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6335, 14338, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6336, 14594, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6337, 18291, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6338, 22641, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6339, 22644, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6340, 22645, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6341, 22647, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6342, 22648, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6343, 22649, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6344, 22650, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6345, 22651, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6346, 22652, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6347, 22653, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6348, 22654, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6349, 22655, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6350, 22657, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6351, 22786, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6352, 23055, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6353, 23056, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6354, 28776, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6355, 28778, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6356, 28779, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6357, 32982, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6358, 32983, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6359, 33198, 'Methotrexate', 'Stomatitis', 'Methotrexate induces stomatitis within the oral mucosa and gastrointestinal tract.  Therapy with methotrexate should be administered with extreme caution in patients with peptic ulcer disease or ulcerative colitis.  If vomiting, diarrhea or ulcerative stomatitis occur, treatment should be discontinued until recovery to avoid the risk of hemorraghic enteritis or intestinal perforation which could be fatal.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6360, 8642, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6361, 11875, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6362, 23373, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6363, 28696, 'Methoxsalen (topical)', 'Photosensitivity Disorders', 'The use of methoxsalen with ultraviolet radiation is contraindicated in patients with a history of photosensitive disease states.  Methoxsalen is a potent photosensitizer that can induce severe burns and marked hyperpigmentation and aging of skin in susceptible patients or when used improperly.  Diseases associated with photosensitivity include lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, and albinism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6364, 8642, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6365, 11875, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6366, 23373, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6367, 28696, 'Methoxsalen (topical)', 'Skin Neoplasms', 'The use of methoxsalen (a psoralen) with ultraviolet radiation (UVA) is contraindicated in patients with melanoma, invasive squamous cell carcinomas, or a history of melanoma.  PUVA (psoralen and UVA photochemotherapy) may be associated with increased risks of squamous cell carcinoma, basal cell carcinoma and melanoma.  Methoxsalen markedly enhances skin reactivity to UVA, and exposure to sunlight and/or UVA can cause premature aging of the skin and skin cancer.  If necessary, patients with a current or past history of multiple basal cell carcinomas or other nonmelanoma skin cancers may be treated with PUVA but should be carefully monitored.  The usual restrictions concerning sun exposure before and after treatment as well as prescribed dosage must be followed closely.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6368, 8642, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6369, 11875, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6370, 23373, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6371, 28696, 'Methoxsalen (topical)', 'Sunburn', 'Patients presenting with a sunburn should not be treated with methoxsalen (a psoralen) and ultraviolet radiation (UVA), since it may be difficult to evaluate the response of these patients to therapy.  The mild, transient erythema normally seen 24 to 48 hours after PUVA (psoralen and UVA photochemotherapy) indicates a therapeutic interaction occurring between the psoralen and UVA but may be masked by a sunburn.  Patients generally should avoid sunbathing for at least 24 hours prior to methoxsalen administration and UVA exposure.  The usual restrictions concerning sun exposure after treatment and the prescribed dosage should also be followed closely to avoid severe burns and other phototoxic reactions.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6372, 17, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6373, 18, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6374, 20, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6375, 21, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6376, 22, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6377, 204, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6378, 205, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6379, 925, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6380, 927, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6381, 940, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6382, 943, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6383, 946, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6384, 948, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6385, 950, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6386, 952, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6387, 1766, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6388, 3339, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6389, 10222, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6390, 14308, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6391, 14309, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6392, 14310, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6393, 14311, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6394, 14392, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6395, 14393, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6396, 14394, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6397, 14400, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6398, 14401, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6399, 14404, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (6400, 25140, 'Aripiprazole', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '', 'DDInter', 0);
